The Hippo Signaling Pathway, Reactive Oxygen Species Production, and Oxidative Stress: A Two-Way Traffic Regulation.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI

Hippo Signaling Pathway* ; Oxidative Stress* ; Protein Serine-Threonine Kinases*/metabolism ; Reactive Oxygen Species*/metabolism; Animals ; Humans

The Hippo signaling pathway is recognized for its significant role in cell differentiation, proliferation, survival, and tissue regeneration. Recently, the Hippo signaling pathway was also found to be associated with oxidative stress and reactive oxygen species (ROS) regulation, which are important in the regulation of cell survival. Studies indicate a correlation between components of the Hippo signaling pathway, including MST1, YAP, and TAZ, and the generation of ROS. On the other hand, ROS and oxidative stress can activate key components of the Hippo signaling pathway. For example, ROS production activates MST1, which subsequently phosphorylates FOXO3, leading to apoptotic cell death. ROS was also found to regulate YAP, in addition to MST1/2. Oxidative stress and ROS formation can impair lipids, proteins, and DNA, leading to many disorders, including aging, neurodegeneration, atherosclerosis, and diabetes. Consequently, understanding the interplay between the Hippo signaling pathway, ROS, and oxidative stress is crucial for developing future disease management strategies. This paper aimed to review the association between the Hippo signaling pathway, regulation of ROS production, and oxidative stress to provide beneficial information in understanding cell function and pathological processes.

Front Mol Neurosci. 2018 Mar 26;11:93. (PMID: 29632474)
Genes Dev. 2008 Jul 15;22(14):1962-71. (PMID: 18579750)
J Hepatol. 2019 Oct;71(4):719-730. (PMID: 31201834)
Cancer Lett. 2008 Jul 18;266(1):37-52. (PMID: 18406051)
FASEB J. 2019 Dec;33(12):14772-14783. (PMID: 31690112)
FEBS J. 2006 Sep;273(18):4264-76. (PMID: 16930133)
Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1785-90. (PMID: 25624491)
Oncogene. 2011 Oct 6;30(40):4208-18. (PMID: 21516123)
J Biochem Mol Toxicol. 2019 Mar;33(3):e22255. (PMID: 30368988)
Dev Cell. 2009 Mar;16(3):411-20. (PMID: 19289086)
Curr Opin Cell Biol. 2017 Dec;49:99-107. (PMID: 29316535)
Oncogene. 2005 Mar 17;24(12):2076-86. (PMID: 15688006)
Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):13839-44. (PMID: 23918388)
Biochem Biophys Res Commun. 2013 Nov 8;441(1):53-8. (PMID: 24134840)
Sci Rep. 2017 Sep 5;7(1):10421. (PMID: 28874754)
Cell Signal. 2012 May;24(5):981-90. (PMID: 22286106)
Genes Dev. 1995 Mar 1;9(5):534-46. (PMID: 7698644)
Onco Targets Ther. 2019 Dec 31;12:11691-11700. (PMID: 32021247)
J Toxicol Sci. 2016 Feb;41(1):105-13. (PMID: 26763397)
Nat Commun. 2024 Jun 15;15(1):5115. (PMID: 38879607)
Oncogene. 2001 Oct 4;20(45):6516-23. (PMID: 11641775)
Am J Cancer Res. 2015 Dec 15;6(1):27-37. (PMID: 27073720)
Exp Mol Med. 2019 Nov 14;51(11):1-12. (PMID: 31723125)
Adv Immunol. 2019;144:87-119. (PMID: 31699221)
Acta Biochim Biophys Sin (Shanghai). 2015 Jan;47(1):10-5. (PMID: 25491506)
Cancer Sci. 2010 May;101(5):1279-85. (PMID: 20219076)
Development. 1995 Apr;121(4):1053-63. (PMID: 7743921)
Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):11930-5. (PMID: 21730131)
Oncogene. 2016 Feb 4;35(5):537-48. (PMID: 25893302)
J Exp Clin Cancer Res. 2022 Jul 12;41(1):219. (PMID: 35820928)
Circ Res. 2014 Jul 18;115(3):354-63. (PMID: 24833660)
J Neurosci. 2011 Jun 29;31(26):9611-9. (PMID: 21715626)
Front Pharmacol. 2022 Sep 16;13:942435. (PMID: 36188539)
Invest Ophthalmol Vis Sci. 2017 Apr 1;58(4):1941-1953. (PMID: 28384715)
Sci Rep. 2016 Mar 16;6:23208. (PMID: 26980066)
Circ Res. 2016 Aug 19;119(5):596-606. (PMID: 27402866)
Cell Physiol Biochem. 2017;44(5):2073-2089. (PMID: 29241219)
Cell Res. 2015 Jul;25(7):801-17. (PMID: 26045165)
Aging (Albany NY). 2023 Jun 14;15(12):5426-5444. (PMID: 37319316)
Proc Natl Acad Sci U S A. 2010 May 4;107(18):8248-53. (PMID: 20404163)
Genes Dev. 2010 Jun 1;24(11):1106-18. (PMID: 20516196)
Science. 2011 Apr 22;332(6028):458-61. (PMID: 21512031)
Cells. 2019 May 08;8(5):. (PMID: 31072060)
Mol Cell. 2014 May 22;54(4):639-50. (PMID: 24813943)
Int J Mol Sci. 2018 Nov 27;19(12):. (PMID: 30486435)
Oncogene. 2002 Feb 14;21(8):1233-41. (PMID: 11850843)
Nat Commun. 2014;5:3315. (PMID: 24525530)
Cancer Lett. 2017 Aug 1;400:175-182. (PMID: 28461246)
Curr Biol. 2016 Apr 25;26(8):1034-42. (PMID: 26996505)
J Clin Invest. 2015 May;125(5):2123-35. (PMID: 25893606)
Breast Care (Basel). 2021 Feb;16(1):6-15. (PMID: 33716627)
Cell Stem Cell. 2018 Jan 4;22(1):35-49.e7. (PMID: 29249464)
Oxid Med Cell Longev. 2015;2015:105135. (PMID: 26273419)
Nat Commun. 2018 Jul 9;9(1):2372. (PMID: 29985391)
Curr Biol. 2008 Mar 11;18(5):311-21. (PMID: 18328708)
Biomed Pharmacother. 2019 May;113:108754. (PMID: 30875659)
Development. 2016 Feb 1;143(3):504-15. (PMID: 26718006)
Cancers (Basel). 2018 Feb 06;10(2):. (PMID: 29415512)
Cell. 2007 Sep 21;130(6):1120-33. (PMID: 17889654)
Cell Cycle. 2013 Dec 15;12(24):3817-23. (PMID: 24107629)
Cancer Cell. 2009 Nov 6;16(5):425-38. (PMID: 19878874)
Hum Exp Toxicol. 2023 Jan-Dec;42:9603271231158039. (PMID: 36781297)
Antioxidants (Basel). 2019 Oct 01;8(10):. (PMID: 31581418)
J Cell Biochem. 2020 Jan;121(1):632-641. (PMID: 31452251)
Genes Dev. 2007 Nov 1;21(21):2747-61. (PMID: 17974916)
EMBO Mol Med. 2017 Jan;9(1):46-60. (PMID: 27940445)
Front Immunol. 2020 Feb 19;11:281. (PMID: 32140159)
Mol Genet Genomics. 2017 Apr;292(2):365-383. (PMID: 28004182)
Oxid Med Cell Longev. 2016;2016:7909186. (PMID: 27818723)
Nat Commun. 2020 Oct 28;11(1):5455. (PMID: 33116140)
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2394-9. (PMID: 22308401)
Basic Res Cardiol. 2014;109(5):435. (PMID: 25168380)
Nat Med. 2013 Nov;19(11):1478-88. (PMID: 24141421)
Nat Med. 2014 Apr;20(4):385-397. (PMID: 24633305)
Dev Cell. 2010 Feb 16;18(2):288-99. (PMID: 20159598)
Cell. 2006 Jun 2;125(5):987-1001. (PMID: 16751106)
Mol Cell Biol. 2008 Apr;28(7):2426-36. (PMID: 18227151)
Cell Death Dis. 2024 Jan 15;15(1):51. (PMID: 38225223)
Cancer Sci. 2021 Oct;112(10):4303-4316. (PMID: 34289205)
Genes Dev. 2012 Jan 1;26(1):54-68. (PMID: 22215811)
Sci Transl Med. 2016 Aug 17;8(352):352ra108. (PMID: 27535619)
Cell. 2005 Aug 12;122(3):421-34. (PMID: 16096061)
Glia. 2014 Apr;62(4):639-48. (PMID: 24464935)
J Mol Cell Biol. 2016 Aug;8(4):328-37. (PMID: 27402810)
Nat Commun. 2016 Jan 12;7:10329. (PMID: 26754915)
ESC Heart Fail. 2022 Feb;9(1):224-235. (PMID: 34931757)
Oxid Med Cell Longev. 2017;2017:8416763. (PMID: 28819546)
Cell Rep. 2013 May 30;3(5):1663-77. (PMID: 23684612)
Theranostics. 2023 Jan 1;13(2):560-577. (PMID: 36632235)
Mass Spectrom Rev. 2015 Mar-Apr;34(2):184-208. (PMID: 24916017)
Science. 1991 Aug 16;253(5021):789-92. (PMID: 1876836)
Oncogene. 2009 Dec 17;28(50):4469-79. (PMID: 19855428)
Oxid Med Cell Longev. 2019 Oct 13;2019:5080843. (PMID: 31737171)
Redox Biol. 2019 Sep;26:101233. (PMID: 31212215)
Nat Rev Gastroenterol Hepatol. 2016 Jun;13(6):324-37. (PMID: 27147489)
Cell. 2014 Aug 14;158(4):833-848. (PMID: 25126788)
Circ Res. 2015 Apr 10;116(8):1431-47. (PMID: 25858067)
Mol Cancer Res. 2019 Jun;17(6):1316-1325. (PMID: 30796177)
Nat Immunol. 2015 Nov;16(11):1142-52. (PMID: 26414765)
Dev Biol. 2012 Jan 1;361(1):103-15. (PMID: 22037235)
Nature. 2017 Oct 12;550(7675):260-264. (PMID: 28976966)
Genes Dev. 2016 Jan 1;30(1):1-17. (PMID: 26728553)
Oncotarget. 2016 Aug 9;7(32):51044-51058. (PMID: 27409837)
Annu Rev Biochem. 2019 Jun 20;88:577-604. (PMID: 30566373)
J Biol Chem. 2000 May 26;275(21):16023-9. (PMID: 10821856)
Biochemistry. 2016 Oct 4;55(39):5507-5519. (PMID: 27618557)
Mol Med Rep. 2012 Feb;5(2):410-4. (PMID: 22012126)
Dev Cell. 2010 Jul 20;19(1):27-38. (PMID: 20643348)
Nat Cell Biol. 2017 Jul 28;19(8):996-1002. (PMID: 28752853)
Dev Cell. 2019 May 6;49(3):425-443.e9. (PMID: 31063758)
JACC Basic Transl Sci. 2018 Nov 12;3(5):639-653. (PMID: 30456335)
Br J Pharmacol. 2019 Oct;176(20):3956-3971. (PMID: 31328787)

Mandate Research Grant No. 346/UN3/2020 Universitas Airlangga

Keywords: Hippo pathway; good health and well-being; oxidative stress; reactive oxygen species; the mammalian Ste20-like kinases; yes-associated protein

EC 2.7.11.1 (Protein Serine-Threonine Kinases)
0 (Reactive Oxygen Species)

Date Created: 20241127 Date Completed: 20241127 Latest Revision: 20241216

20250114

PMC11592687

10.3390/cells13221868

39594616